KLP Kapitalforvaltning’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$74.9M Buy
3,111,232
+127,500
+4% +$3.34M 0.24% 74
2026
Q1
$83.8M Sell
2,983,732
-90,200
-3% -$2.4M 0.33% 51
2025
Q4
$76.5M Sell
3,073,932
-15,800
-0.5% -$398K 0.3% 57
2025
Q3
$78.7M Buy
3,089,732
+82,300
+3% +$2.03M 0.31% 51
2025
Q2
$72.9M Buy
3,007,432
+289,900
+11% +$6.76M 0.31% 52
2025
Q1
$68.9M Sell
2,717,532
-1,800
-0.1% -$47.1K 0.34% 50
2024
Q4
$72.1M Buy
+2,719,332
New +$73.8M 0.34% 44

Other funds holding PFE

KLP Kapitalforvaltning's PFE Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Pfizer (PFE) stake by 4.3% in Q2 2026, buying an estimated $3.34M and bringing the position to 3,111,232 shares worth $74.9M. The position accounts for 0.24% of the portfolio, ranked #74.

KLP Kapitalforvaltning first reported a position in PFE in Q4 2024 and has held it in 7 quarters since. The position peaked at $83.8M in Q1 2026. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • KLP Kapitalforvaltning held 3,111,232 shares of Pfizer worth $74.9M as of Q2 2026.
  • KLP Kapitalforvaltning bought 127,500 Pfizer shares in Q2 2026, an estimated $3.34M.
  • Pfizer made up 0.24% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #74 holding.
  • KLP Kapitalforvaltning first reported a position in Pfizer in Q4 2024 and has held it in 7 quarters since.
  • KLP Kapitalforvaltning's Pfizer position peaked at $83.8M in Q1 2026.
  • 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.